CLINICAL EFFECT OF A CHINESE HERBAL THERAPY IN HUMAN ASTHMA-PHASE II, PROJECT 2

中草药治疗人类哮喘的临床效果 - 第二阶段，项目 2

• 批准号: 7953734
• 负责人: Xiu-Min Li
• 金额: $ 0.42万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7953734
• 关键词: Adrenal Cortex Hormones; Adverse effects; Asthma; Botanicals; Breathing; China; Chinese Herbs; Clinical Research; Complementary and alternative medicine; Computer Retrieval of Information on Scientific Projects Database; Drug usage; Funding; Grant; Herb; Herbal Medicine; Human; Institution; Intervention; Leukotrienes; Oral; Outcome; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phytotherapy; Prevalence; Public Health; Reporting; Research; Research Personnel; Resources; Respiratory physiology; Societies; Source; Symptoms; Uncertainty; United States National Institutes of Health; anti-IgE; base; clinical effect; effective therapy; improved; inhibitor/antagonist

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 9/16/2008 Hypothesis: The botanical drug, ASHMI, will be an effective treatment for asthma with fewer side effects that currently used drugs such as inhaled corticosteroids (ICSs). Asthma is a major public health problem worldwide, particularly in westernized societies and has continued to increase in prevalence over the past two decades. ICSs have become the first-line treatment for persistent asthma even though significant side effects have been reported. New asthma medications, including leukotriene inhibitors and anti-IgE, have shown only marginal benefits. Patients have increasingly turned to complementary and alternative medicine (CAM) for treatment of their asthma, despite the uncertainty of its benefits due a lack of well-controlled scientific studies. We have developed a Chinese herbal formula composed of 3 herbs called ASHMI (anti-asthma herbal medicine intervention). A previous study in China of 91 moderate-severe persistent asthmatics showed that oral ASHMI significantly improved lung function and reduced symptom scores. Most importantly, no severe side effects were observed. We recently completed a Phase I study at Mount Sinai that showed that ASHMI has good tolerability without significant side effects. Based on these preliminary studies, we hypothesize that ASHMI will be safe and effective in improving the outcome of asthma in atopic patients with persistent moderate-severe asthma.

这个子项目是众多研究子项目之一